BioTrove Announces R&D Collaboration with Constellation Pharmaceuticals
BioTrove, Inc. announced it has formed a research collaboration with Constellation Pharmaceuticals in which Constellation will utilize BioTrove's RapidFire® mass spectrometry (RF-MS) system to accelerate development of novel therapeutics in the emerging field of epigenetics.
Constellation was founded in April of 2008 as the first biopharmaceutical company focused on discovering and developing novel drugs targeting selective regulators of epigenetic function through a $32 million Series A financing led by Third Rock Ventures, The Column Group and Venrock.
Constellation researchers will use BioTrove's RapidFire screening and analysis system to explore a new class of drugs regulating the epigenome to alter gene expression by manipulation of chromatin's histone proteins. Slight modifications in protein structure are difficult to identify using conventional screening methods; however, RapidFire technology provides label-free, biologically relevant data so that researchers can determine which compounds may be validated or compromised before further investigation, according to the company. Compressing the time to develop assays for this unique class of targets will enable Constellation to screen its novel epigenetic drug candidates more efficiently and effectively than current available technologies.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!

Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!